|  | Rosatom digital press office <https://atommedia.online/en/>  | **Press release**26.03.24 |
| --- | --- | --- |

**Rosatom to cooperate with Med Pharma Group to promote the medical device “Tianox” on the Egyptian market**

*The agreement was signed on sidelines of the ATOMEXPO-2024*

On March 26, 2024, in Sochi, Russia, Rusatom RDS (part of Rosatom State Corporation) and the Egyptian company “Med Pharma Group” signed a roadmap for cooperation in promoting the medical device “Tianox” in the healthcare and pharmaceutical market of the Arab Republic of Egypt.

The document was signed at the XIII International Forum ATOMEXPO-2024 by CEO of Rusatom RDS, Alexey Asinovsky, as well as the director of Rosatom's country office in Egypt, Murad Aslanov, from the Russian side and Managing Director of Med Pharma Group, Moustafa Helal, from Egyptian side.

“Tianox” is a Russian device for nitric-oxide therapy for adults and children (including newborns), an innovative development by specialists of the Russian nuclear industry. The device is used in pulmonology, cardiothoracic surgery, transplantation, neonatology, rehabilitation, and other fields. “Tianox” synthesizes nitric-oxide itself, delivers it to the patient's lungs, and monitors the concentration. In December 2023, the device received its first international certificate: its use was approved by regulators in Belarus.

Anatoly Myalitsyn, Specialized Medical Technology Section Director at Rusatom RDS said: “The signing of this agreement is an important step towards opening up new prospects and expanding the geography of activities for our company. Therefore, as part of the roadmap implementation, we plan registering the device in the territory of the Republic as a medical device, as well as conducting seminars aimed at exchanging experience between medical specialists of the Russian Federation and the Arab Republic of Egypt. We are confident that our cooperation with Egyptian partners will be successful and mutually beneficial for all parties.”

Earlier, the parties signed an agreement to cooperate in scientific and technical fields and to implement the use of nitric-oxide based on the “Tianox” device in medical institutions in the Arab Republic of Egypt. Over the past year, participants in the Egyptian healthcare and pharmaceutical market have appreciated the uniqueness of the medical device and intend to continue cooperation. It is expected Egyptian doctors will start using “Tianox” initially for the treatment of newborns and children of older ages with pulmonary arterial hypertension, and in the future – for the treatment and rehabilitation of adults with various diagnoses, including cardiovascular diseases.

Specialists from Rusatom RDS are ready to provide support and consultations on technical issues, as well as offer training programs and master classes for medical workers in Egypt.

**For reference:**

*Rusatom RDS acts as a comprehensive integrator of Rosatom’s high-tech civilian products in the fields of machinery, electronics, and specialised medical equipment. The company coordinates work in new business areas, providing customers with comprehensive solutions, from design and manufacturing to after-sales service throughout the product’s lifecycle.*

*Nitric-oxide is used for therapy in pre-capillary pulmonary hypertension, pulmonary thrombosis, embolism, viral pneumonia, ischemic stroke, during therapy in the postoperative period, and in many other cases.*

*The International Forum ATOMEXPO, organized with the support of the State Atomic Energy Corporation Rosatom, has been held since 2009. It is the largest business and exhibition platform where leaders of industry companies and top experts discuss the development tasks of nuclear technologies, strengthen partnerships, and exchange best practices. The forum format includes an exhibition and an extensive business program, with the main topics traditionally being the development of nuclear energy as an environmentally friendly energy source; human capital management; nuclear energy infrastructure development; financing and investment in energy; development of non-energy nuclear technologies, and many others. The forum operator is ATOMEXPO LLC.*

*As part of demonstrating Rosatom's commitment to the climate agenda, carbon footprint compensation for the XIII International Forum ATOMEXPO-2024 will be provided using special certificates.*